Investigational KHN922 for advanced solid tumors
Part of Cancer clinical trials.
This study tests an investigational medicine called KHN922 for advanced or unresectable solid tumors that haven't responded to other treatments. The goal is to see if it is safe and how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old and have a life expectancy of at least 3 months.
- You need a confirmed diagnosis of advanced or unresectable solid tumors that have not responded to standard treatments or cannot receive them.
- You should have at least one tumor that can be measured on a CT or MRI scan.
- You must be in generally good physical condition (able to do light activities, not bedridden) — this is called ECOG status 0 or 1.
- You must not have had major surgery, certain cancer treatments (like chemotherapy, radiation, or targeted drugs) within specified timeframes before joining.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational medicine called HS-20117-2 for people with advanced solid tumors that haven't responded to other treatments. The goal is to see if it is safe and if it might help shrink or control the tumor.
This trial tests an experimental drug called MHB046C for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow their growth.
This trial tests a new drug, JSKN022, for people with advanced solid tumors that have stopped responding to standard treatments or are not eligible for them. The goal is to see if the drug is safe and effective.
This trial tests a new drug called MHB042C for people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective.
This study tests a new experimental drug called KH815 for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if the drug is safe and how well it works against different types of cancer.
This Phase 1 trial tests KH617, a new treatment, in adults with advanced cancers to see if it can be given safely and whether it shows signs of benefit. It is especially focused on tumors that have few or no standard treatment options, including certain brain tumor recurrences.
Hear when a new Advanced Solid Tumors Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.